Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 11-20 of 24 (Search time: 0.002 seconds).
previous
1
2
3
next
Item hits:
Preview
Issue Date
Title
Author(s)
2009
Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapy
Hughes, T.
;
Hochhaus, A.
2003
Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR
Hui, C.
;
Goh, K.
;
White, D.
;
Branford, S.
;
Grigg, A.
;
Seymour, J.
;
Kwan, Y.
;
Walsh, S.
;
Hoyt, R.
;
Trickett, A.
;
Rudzki, Z.
;
Ma, D.
;
To, L.
;
Hughes, T.
2004
Clinical resistance to imatinib: mechanisms and implications
Hochhaus, A.
;
Hughes, T.
2009
Impact of baseline BCR-ABL mutations on response to Nilotinib in patients with chronic myeloid leukemia in chronic phase
Hughes, T.
;
Saglio, G.
;
Branford, S.
;
Soverini, S.
;
Kim, J.
;
Muller, M.
;
Martinelli, G.
;
Cortes, J.
;
Beppu, L.
;
Gottardi, E.
;
Dongho, K.
;
Erben, P.
;
Shou, Y.
;
Haque, A.
;
Gallagher, N.
;
Radich, J.
;
Hochhaus, A.
2009
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
Branford, S.
;
Vaz de Melo, J.
;
Hughes, T.
2005
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib
Dewar, A.
;
Cambareri, A.
;
Zannettino, A.
;
Boog, B.
;
Doherty, K.
;
Hughes, T.
;
Lyons, A.
2006
OCT-1-mediated influx is a key determinant of the intraceflular uptake of imatinib but not nilotinib, (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib
White, D.
;
Saunders, V.
;
Dang, P.
;
Engler, J.
;
Zannettino, A.
;
Cambareri, A.
;
Quinn, S.
;
Manley, P.
;
Hughes, T.
2009
Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet
Baccarani, M.
;
Cortes, J.
;
Pane, F.
;
Niederwieser, D.
;
Saglio, G.
;
Apperley, J.
;
Cervantes, F.
;
Deininger, M.
;
Gratwohl, A.
;
Guilhot, F.
;
Hochhaus, A.
;
Horowitz, M.
;
Hughes, T.
;
Kantarjian, H.
;
Larson, R.
;
Radich, J.
;
Simonsson, B.
;
Silver, R.
;
Goldman, J.
;
Hehlmann, R.
2009
Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial
Apperley, J.
;
Cortes, J.
;
Kim, D.
;
Roy, L.
;
Roboz, G.
;
Rosti, G.
;
Bullorsky, E.
;
Abruzzese, E.
;
Hochhaus, A.
;
Heim, D.
;
De Souza, C.
;
Larson, R.
;
Lipton, J.
;
Khoury, J.
;
Kim, H.
;
Sillaber, C.
;
Hughes, T.
;
Erben, P.
;
Tornout, J.
;
Stone, R.
2007
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
White, D.
;
Saunders, V.
;
Dang, P.
;
Engler, J.
;
Venables, A.
;
Zrim, S.
;
Zannettino, A.
;
Lynch, K.
;
Manley, P.
;
Hughes, T.
Discover
Author
9
Hochhaus, A.
8
Branford, S.
5
White, D.
4
Cortes, J.
4
Goldman, J.
4
Grigg, A.
4
Larson, R.
4
Radich, J.
4
Rudzki, Z.
4
Saglio, G.
.
next >
Subject
24
Benzamides
24
Humans
24
Imatinib Mesylate
24
Pyrimidines
18
Leukemia, Myelogenous, Chronic, B...
13
Antineoplastic Agents
13
Fusion Proteins, bcr-abl
10
Male
9
Adult
9
Drug Resistance, Neoplasm
.
next >
Date issued
5
2009
2
2008
2
2007
3
2006
3
2005
1
2004
6
2003
2
2002